CI vs HALO: fair value comparison
The Cigna Group and Halozyme Therapeutics, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HALO currently sits closer to the top of our discount ranking. HALO carries the stronger quality grade.
| CI | HALO | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $280.76 | $107.72 |
| 12-month range | $244.41–$289.26 | $63.96–$107.72 |
| Sector rank | #39 of 113 Healthcare | #36 of 113 Healthcare |
| Quality grade | F | A |
| Leverage | Moderate | High |
| Margin trend | Expanding | Contracting |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CI fair value analysis · HALO fair value analysis